{"id":783436,"date":"2026-01-08T10:03:01","date_gmt":"2026-01-08T10:03:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=783436"},"modified":"2026-01-08T10:03:01","modified_gmt":"2026-01-08T10:03:01","slug":"medvi-expands-access-to-semaglutide-online-with-updated-program-trusted-by-100000-patients","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/medvi-expands-access-to-semaglutide-online-with-updated-program-trusted-by-100000-patients_783436.html","title":{"rendered":"MEDVi Expands Access to Semaglutide Online With Updated Program Trusted by 100,000 Patients"},"content":{"rendered":"
\n
\"MEDVi<\/a><\/div>\n
\n
MEDVi highlights board-certified physician oversight, transparent pricing starting at $179\/month, and 24\/7 clinical support for GLP-1 weight-loss treatment delivered through telehealth.<\/div>\n<\/div>\n<\/div>\n
MEDVi, a telehealth platform serving more than 100,000 patients, today announced continued nationwide momentum as Americans seek more convenient, clinician-supervised access to GLP-1 weight-loss medications, including semaglutide, through an all-inclusive online program designed to reduce friction, improve support, and set a higher bar for patient experience.<\/div>\n

Disclosure: This announcement is for informational purposes only and does not constitute medical advice. Compounded semaglutide is not FDA-approved. This release may include links or references for which the issuer may receive compensation, at no additional cost to the reader.<\/em><\/p>\n

As demand for GLP-1 medications grows, many patients report a confusing landscape of inconsistent pricing, extended wait times for medical review, and limited follow-up care once a prescription is issued. MEDVi says its model was built to address those concerns with a streamlined intake process<\/a>, board-certified physician review, and ongoing support that remains available throughout treatment.<\/p>\n

“Patients deserve clarity, clinical oversight, and real support—especially when starting a medication that can come with questions or side effects,” a MEDVi spokesperson said. “Our goal is to make GLP-1 treatment more accessible and more responsible: medically supervised, straightforward to start, and supported at every step.”<\/p>\n

Why Patients Are Choosing MEDVi for Semaglutide Online<\/strong><\/p>\n

According to MEDVi<\/a>, patients often encounter common pain points across the online weight-loss marketplace—monthly costs that can exceed several hundred dollars, added consultation or membership fees, and delays when trying to speak with a qualified clinician. MEDVi’s program is structured as a single monthly price intended to include key services patients typically need during GLP-1 treatment.<\/p>\n

MEDVi program highlights include:<\/p>\n